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Lupus Erythematosus 
• Autoimmune multisystem disease, affects 
women>>men 
• Skin disease present at some time in the 
course of disease in 70% 
• Systemic features include: arthritis, serositis, 
renal disease, CNS disease, etc 
 
Acute Cutaneous Lupus 
Erythematosus 
• Malar rash 
• Erythema and 
photosensitivity 
• Non-scarring 
• Associated with SLE 
Subacute Cutaneous Lupus 
Erythematosus 
• Very photosensitive 
• Annular or papulosquamous  
• Often Anti-Ro antibodies 
• Often mild systemic disease 
Chronic Cutaneous Lupus 
Erythematosus 
• Scaly plaques with follicular 
plugging 
• Scarring 
• If no evidence of SLE at presentation 
only 5% risk in adults developing 
SLE (risk higher in children) 
 
Lupus Profundus (Lupus panniculitis) 
• Indurated plaques +/- surface features 
of LE 
• May be seen in SLE or DLE 
Cutaneous Lupus Treatment 
• Sunscreens 
• Topical steroids 
• Topical calcineurin inhibitors 
• Oral antimalarials (hydroxychloroquine 200mg 
QD-BID, also chloroquine, quinacrine) 
• Prednisone 
• Other systemic immunosuppressants 
Cutaneous features of Dermatomyositis 
• Heliotrope erythema, particularly of eyelids 
• Gottren’s papules 
• Nail fold capillary changes 
• Shawl-like rash 
Dermatomyositis 
• Characteristic skin findings typically 
associated with an inflammatory myopathy.  
“Amyopathic” disease occurs rarely.  
Bimodal age distribution. F>>M 
• Systemic findings:  
– muscle weakness 
– Pulmonary interstitial fibrosis in 15-30% 
– Calcinosis in children 
– Associated malignancy in 30% of adults 
Dermatomyositis Treatment 
• For skin: sunscreens, topical steroids, topical 
calcineurin inhibitors 
• Prednisone 
• Methotrexate, other systemic 
immunosuppressants 
• IVIG 
Scleroderma (Systemic Sclerosis) 
• Systemic autoimmune disease; F>M 
• Symmetric induration of fingers, hands and 
face 
• Raynaud’s phenomenon 
• Pulmonary fibrosis and hypertension 
• Esophageal dysmotility 
• Renal Disease 
 
Scleroderma – CREST Syndrome 
Calcinosis 
Raynaud’s 
Esophageal 
involvement 
Sclerodactyly 
Telangiectasia 
*Associated with anti-centromeric 
antibodies 
Raynaud’s Treatment 
• Keep warm 
• Stop smoking 
• Calcium channel blockers (nifedipine)+/- 
angiotensin II receptor blockers (losartan) 
Morphea therapy 
• For localized disease: Topical steroids 
Calcipotriene (Dovonex), calcineurin inhibitors 
• Widespread or linear morphea: Prednisone, 
methotrexate, antimalarials 
(hydroxychloroquine), Phototherapy: PUVA, 
UVA1, Physical therapy 
Skin disorders in RA 
• Rheumatoid nodules 
• Rheumatoid vasculitis 
• Felty Syndrome 
• Pyoderma gangrenosum 
• Rheumatoid neutrophilic dermatosis 
• Interstitial granulomatous dermatitis / 
palisaded neutrophilic and granulomatous 
dermatitis 
• Rash of JRA / adult onset Still disease 
Rheumatoid Arthritis 
• 1% of population in US and UK 
• F:M = 2.5:1 
• 15-30% concordance in monozygotic twins 
• Risk factors 
– Smoking 
– HLA-DRB1*04, HLA-C*03 
Classic Rheumatoid Nodules 
• 25% of all RA patients, 40% of seropositive 
patients, 75% of Felty syndrome patients,  
• Whites>Blacks  
• M>F 
• May be dermal, subcutaneous or even visceral 
• Involve areas prone to mild chronic irritation 
• Pathogenesis ? trauma leads to immune 
complex deposition with resultant vasculitis 
with ischemia, and palisaded granulomatous 
inflammatory reaction 
 
Rheumatoid Nodules 
• Complications: infection, ulceration, creation 
of a synovial fistula 
• Treatment: usually none required 
– Can excise, but recurrences are frequent 
– IL steroids can help shrink lesions, but carry some 
risk of persistent drainage or infection 
– Nodules may improve with therapy, but not 
always, and may actually worsen 
Rheumatoid Vasculitis 
• 30 year incidence in RA of 3.6% 
• Typically occurs in long standing disease (may 
be “burnt out”) in individuals with rheumatoid 
nodules 
• Associated factors 
– High titer RF positivity 
– Joint erosions 
– Other extra-articular manifestations 
– Male gender (males also have more severe 
disease) 1/9 men, 1/38 women 
– Smoking 
Rheumatoid Vasculitis 
• Leukocytoclastic vasculitis- immune complex 
mediated 
• Subclinical vasculitis very common  
• Vascular immune complexes found in 20-65% of 
normal skin in RA patients.  
– Rates correlate with disease activity and extra-articular 
manifestations 
• Involves small and medium sized vessels and 
presentation varies accordingly from palpable 
purpura to ulceration. 
 
Rheumatoid Vasculitis Presentations 
• Leg ulceration: most often as painful punched out 
ulcers on the pretibia or lateral malleolus. The 
differential is often pyoderma gangrenosum. 
• Sensory or motor neuropathy: relatively frequent, 
presenting as mononeuritis multiplex. 
• Weight loss, fever seen with systemic vasculitis 
• Bywaters lesions:  small nail fold or digital pulp 
infarctions caused by small vessel vasculitis and are 
usually not associated with systemic vasculitis.  
Digital gangrene is associated with systemic disease. 
• Treatment: Steroids, Rituximab, cyclophosphamide 
 
Felty Syndrome 
• Triad of arthritis, leukopenia and 
splenomegaly described in 1924 by Felty. 
• 1% of RA patients 
• Whites>>blacks, F:M 1.6:1 
• Typically in patients with long-standing, 
seropositive , destructive arthritis 
• 75% have rheumatoid nodules 
• 22% have leg ulcers  
Felty Syndrome 
• Ulcers located over shins and ankles, often 
deep and chronic 
• Mortality of 25% with death due to sepsis 
• Increased risk of rheumatoid vasculitis 
Felty Syndrome Treatment 
• Current drugs of choice: Methotrexate and 
gold 
• Role of biologics not clear 
• G-CSF for reversal of granulocytopenia with 
severe infection 
• Splenectomy reserved for severe 
granulocytopenia (<1000/mm3) and recurrent 
infections despite aggressive medical therapy 
 
Pyoderma Gangrenosum 
• Arthritis is associated with approximately 25% 
of cases of PG (references vary, but about half 
of the arthritis cases are RA). 
• Other systemic associations include 
inflammatory bowel disease and hematologic 
malignancies 
• 50% of cases are idiopathic 
Pyoderma Gangrenosum: Differential 
Diagnosis 
• Infection 
• Vasculitis 
• Tumor 
• Coagulopathies 
• Cutaneous Crohn disease 
• Brown recluse spider bites 
• Factitial ulceration 
Pyoderma Gangrenosum: Biopsy 
• Major purpose of biopsy is to exclude other 
diseases in the differential 
• Dense neutrophilic inflammation centrally, 
usually with ulceration. Laterally inflammation 
may be more lymphocytic.  
• Stains and cultures needed to exclude 
infection. 
 
Pyoderma Gangrenosum 
• Treatment:  
• Local wound care: moist dressings. Avoid 
aggressive debridement 
• Topical corticosteroids or calcineurin 
inhibitors: Helpful in some cases.  Intralesional 
corticosteroids may be useful, but concerns 
for pathergy. 
• Systemic treatment usually required 
 
 
Pyoderma Gangrenosum: Systemic Therapy 
• Prednisone 0.5-1.0 mg/kg. Due to long term side 
effects, steroid sparing agents usually added if 
treatment needed for more than 2-4 weeks. Acts 
quickly.  
• Cyclosporine 4-5mg/kg/day. Acts fairly quickly 
• Infliximab 5mg/kg weeks 0,2,6, then q6-8.  Fast 
acting, useful in the setting of RA or inflammatory 
bowel disease. Contraindicated in CHF, TB, MS. 
• Azathioprine, MTX, mycophenolate mofetil, dapsone, 
minocycline used as steroid sparing agents. None act 
quickly 
Palisaded neutrophilic and granulomatous 
dermatitis 
• Associated diseases all associated with 
immune complex formation 
• Many authors suggest that immune complex-
mediated damage to dermal vessels results in 
complement activation, recruitment of 
neutrophils and resultant damage to dermal 
collagen. A granulomatous response to the 
damaged collagen then ensues.  
 
 
• Palisaded neutrophilic and granulomatous 
dermatitis, interstitial granulomatous 
dermatitis, rheumatoid papules, granuloma 
annulare-like drug eruption - all refer to this 
basic histologic reaction pattern. 
• This reaction pattern is not specific and may 
be associated with connective tissue disease, 
systemic vasculitis, lymphoproliferative 
disorders, drugs and inflammatory bowel 
disease.  
Adult Still disease 
• Fever > 39o C spiking in late afternoon or 
evening 
• Arthritis or arthralgia 
• RF<1:80, ANA<1:100 
• 2 of: 
– Leukocytosis of >15,000 
– Pleuritis or pericarditis 
– Hepatosplenomegaly or adenopathy 
– Still rash (90% of patients) 
• Salmon colored macular or papular on trunk or limbs, 
often appears during fever spikes 

